Pradaxa Lawsuit Information

In August of 2012, Pradaxa manufacturer issued a report that the use of the drug has reached record levels.  Meanwhile, a federal judge came up with a ruling that the manufacturer will thus have to expect thousands of potential injury and death lawsuits over their product's internal bleeding side effects. The drug, Pradaxa, is used as blood thinner.  
It is prescribed to patients for strokes prevention while it is also prescribed to prevent blood clots in patients with atrial fibrillation. The manufacturer, Boehringer Ingelheim, on August 27, 2012, announced that Pradaxa has reached prescription of one million patient-years of combined time, and has been used also in more than 70 countries all over the world.  
Although existing only on the market since October, 2010, the drug has earned over $1 billion. The drug was originally approved for use in Europe in 2008.  This was followed by the United States approval in 2010 and has the endorsement of the American Heart Association, not to mention the American College of Cardiology Foundation for non-valvular atrial fibrillation. Following these endorsements, Pradaxa use rose up.  
Nonetheless, the increased use of Pradaxa came with detrimental events. Last year, in consequent developments, the FDA has issued an announcement that it was launching an investigation into Pradaxa safety after receiving 3,781 side effects reports and 542 death reports among users of the drug.  The figures were higher than the expected outcome. Judge Schedules Beginning of Pradaxa Lawsuit Trials In Illinois, a central court was recently established to handle the rising number of victims who have filed a Pradaxa lawsuit. 
On July 25th, the overseeing judge, the Hon. David Herndon, issued a ruling denying Boehringer Ingelheim's legal move to dismiss Pradaxa bleeding lawsuits. Judge Herndon has also scheduled an initial hearing for October 3 of 2012 and indicated trials should start in 18 to 24 months. This development follow experts' findings that link the blood thinner Pradaxa to severe internal bleeding, not to mention hundreds of users filing lawsuits for injury or death. MedWatch, the reporting service of the FDA, reported that several hundred complaints of several internal bleeding resulting to death in some cases have been received by the agency. Because of the alarming news, personal injury firms have regularly updates on lawsuit against Pradaxa manufacturer by setting up online news sites. 
The FDA's MedWatch, on top of the primary side effects and problems wrought by the drug, attributed the use of Pradaxa to further adverse events compared to nearly 99% of other drugs found in the market. Included in this list of dangerous, not to mention potentially fatal eventsFree Web Content, are the following: - Increased risk of a heart attack- Hemorrhaging of the Kidneys- Hemorrhaging of the brain- Hemorrhaging of the gastrointestinal system. There have been numerous alarming reports coming from doctors in which patients taking Pradaxa bled to death. Even more alarming is the fact that there is no reversal agent for Pradaxa compared to other anticoagulants such as Coumadin and Wayfarin